We are the first to offer PEA in a high-quality and directly applicable format for unique end products
Palmitoylethanolamide in NutraCups
LIPOSOMA proudly announces our newest product range, called NutraCups®. For LIPOSOMA’s NutraCups we selected our finest liposome ingredients and placed these in cup cartridges that are designed for standard coffee cup extraction machines, which are present in almost every household. Every NutraCup produces a perfect liposome dispersion upon hot water extraction, containing high-quality active ingredients. This technology is especially well suited for active ingredients that require higher daily doses, like the highly interesting bioactive compound palmitoylethanolamide (PEA). PEA is usually administered in a high starting dosage of 1200 mg per day, followed after two months by a daily maintenance dosage of 600 mg, which is a dose that can now be provided in liposomal form because of our NutraCup technology.
Orally administered PEA in the form of capsules containing conventional powder without liposomes is poorly absorbed by the body. The warm liposomal PEA dispersion produced with PEA NutraCups ensures PEA is optimally encapsulated, protected and delivered to the intestinal site of uptake in its active form after oral intake. Moreover, because the actual liposome dispersion is produced at home right before consumption, no preservatives are needed in the product.
What is PEA?
Palmitoylethanolamide (PEA) is an endogenous lipid present in various human tissues including the brain, liver, eyes and muscles. It is produced from membrane phospholipids and exerts a variety of functions . PEA can naturally be derived from several food sources, like peanuts, soybeans or other beans . PEA is a highly interesting bioactive ingredient according to scientific literature.
Benefits of NutraCups
To enable successful liposomal encapsulated PEA, LIPOSOMA developed a new technology called NutraCups. With this technology, all ingredients of liposomal PEA are provided in a cup cartridge and liposomes are formed upon extraction of the cups with warm water. The cups are made compatible with standard coffee cup extraction machines, so that the liposomal PEA beverage can be produced at home right before consumption. At LIPOSOMA we discovered that only this way complete solubilization of the PEA molecules in the matrix can be ensured and the required dose can be administered and delivered for intestinal uptake in its active form. Furthermore, the NutraCups technology has the advantage that no preservatives are needed.
Why take liposomal PEA?
Featuring natural health ingredients encapsulated in liposomes, the NutraCups technology can bring out the important benefit that the ingredients are protected against premature degradation . This allows the PEA in our supplement to arrive in the gut without being broken down first. Moreover, the phospholipids of which the liposomal matrix is composed provide additional health benefits themselves. Their main constituent is phosphatidylcholine, which incorporates bioactive choline. Choline contributes to normal liver function and lipid metabolism .
“Discover all the benefits of our liposome technology that along with our outstanding ingredients help us to establish valuable relationships with our business partners. “
LIPOSOMA Nutraceuticals; experts in liposomes
LIPOSOMA manufactures branded and white label liposomal supplements.
Our high-end liposomal nutraceuticals are guaranteed by the academic qualifications of our team and its commitment to scientific excellence.
Our liposome technology offers many advantages for nutritional supplement producers, the food sector and consumers. Our liposomal vitamins and other nutraceuticals are available as raw materials, capsules, liquids and many other tailored solutions.
Would you like to learn more? Give us a call at 0031 20 237 36 00
 Iannotti, A., Di Marzo, V., Petrosino, S. (2016). Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. Progress in Lipid Research 62:107-128.
 Petrosino, S., & Di Marzo, V. (2017). The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. British Journal of Pharmacology, 174(11), 1349-1365.
 Fricker, G., Kromp, T., Wendel, A., Blume, A., Zirkel, J., Rebmann, H., Setzer, C., Quinkert R., Martin, F., Muller-Goymann, C. (2010). Phospholipids and lipid-based formulations in oral drug delivery. Pharmaceutical Research 27(8), 1469-1486.
 Zeisel, S. H., Klatt, K. C., & Caudill, M. A. (2018). Choline. Advances in Nutrition, 9(1), 58-60.